{"id":"benralizumab-arm-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benralizumab targets the IL-5 receptor alpha (CD125) expressed on eosinophils and basophils, blocking IL-5 signaling and triggering antibody-dependent cellular cytotoxicity (ADCC) to eliminate these cells. This mechanism reduces eosinophilic inflammation in the airways and tissues, making it effective for eosinophil-driven inflammatory diseases. The drug is particularly useful in conditions characterized by elevated eosinophil counts.","oneSentence":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:00.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe eosinophilic asthma"},{"name":"Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"}]},"trialDetails":[{"nctId":"NCT06862206","phase":"","title":"This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1000},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT07444567","phase":"PHASE3","title":"Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-27","conditions":"Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)","enrollment":230},{"nctId":"NCT04191304","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-20","conditions":"Hypereosinophilic Syndrome","enrollment":134},{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT06465485","phase":"PHASE3","title":"STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-28","conditions":"Severe Eosinophilic Asthma","enrollment":504},{"nctId":"NCT05251909","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-01-18","conditions":"Eosinophilic Gastritis, Eosinophilic Gastroenteritis","enrollment":12},{"nctId":"NCT04221802","phase":"","title":"Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-12-23","conditions":"Severe Asthma","enrollment":76},{"nctId":"NCT06734884","phase":"PHASE2","title":"Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2025-01-06","conditions":"DRESS Syndrome","enrollment":96},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT05384938","phase":"PHASE4","title":"FAsenra Safety Trial in India","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-19","conditions":"In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India","enrollment":139},{"nctId":"NCT05271526","phase":"","title":"Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-16","conditions":"Severe Eosinophilic Asthma","enrollment":3},{"nctId":"NCT04612725","phase":"PHASE2","title":"A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-10-27","conditions":"Chronic Spontaneous Urticaria","enrollment":159},{"nctId":"NCT06288516","phase":"PHASE4","title":"BenRalizumab Effect on Airway Remodeling in Severe asTHma","status":"RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2024-03-01","conditions":"Asthma; Eosinophilic, Airway Remodeling","enrollment":45},{"nctId":"NCT02808819","phase":"PHASE3","title":"A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Asthma","enrollment":447},{"nctId":"NCT02869438","phase":"PHASE3","title":"A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-09","conditions":"Asthma","enrollment":233},{"nctId":"NCT02258542","phase":"PHASE3","title":"A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-19","conditions":"Asthma","enrollment":2133},{"nctId":"NCT02968914","phase":"PHASE1","title":"Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-04","conditions":"Asthma, Chronic Obstructive Pulmonary Disease","enrollment":180},{"nctId":"NCT02155660","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-25","conditions":"Moderate to Very Severe Chronic Obstructive Pulmonary Disease","enrollment":2255},{"nctId":"NCT02138916","phase":"PHASE3","title":"Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-13","conditions":"Moderate to Very Severe Chronic Obstructive Pulmonary Disease","enrollment":1656},{"nctId":"NCT02918071","phase":"PHASE3","title":"Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-10","conditions":"Asthma","enrollment":121},{"nctId":"NCT02075255","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-28","conditions":"Asthma","enrollment":220},{"nctId":"NCT02322775","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-02","conditions":"Asthma","enrollment":211}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Benralizumab Arm A","genericName":"Benralizumab Arm A","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. Used for Severe eosinophilic asthma, Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype), Eosinophilic granulomatosis with polyangiitis (EGPA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}